Neurocrine Biosciences | Créances Commerciales



Trade Debtors Changement Date
AbbVie USD 10.92B 553M 2024-12
Acadia Pharmaceuticals USD 113.71M 9.02M 2025-03
Agios Pharmaceuticals USD 3.34M 765K 2025-03
ALKERMES USD 321.75M 72.97M 2025-03
Alnylam Pharmaceuticals USD 418.04M 12.73M 2025-03
Amgen USD 8.13B 1.35B 2025-03
Biogen USD 2B 127.7M 2025-03
BioMarin Pharmaceutical USD 739.18M 78.64M 2025-03
Cytokinetics USD 2.01M 14.64M 2025-03
Dynavax Technologies USD 56.56M 9.65M 2025-03
Exelixis USD 281.64M 16.2M 2025-04
Gilead Sciences USD 4.39B 32M 2025-03
Halozyme Therapeutics USD 304.62M 3.83M 2025-03
Incyte USD 823.13M 30.02M 2025-03
Ionis Pharmaceuticals USD 39.71M 52.48M 2025-03
Neurocrine Biosciences USD 479.1M 2M 2024-12
Pfizer USD 14.74B 32M 2025-03
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 5.56B 650.9M 2025-03
Repligen USD 147.41M 13.3M 2025-03
Sarepta Therapeutics USD 724.52M 74.8M 2025-03
Teva Pharmaceutical Industries USD 3.38B 325M 2025-03
Ultragenyx Pharmaceutical USD 123.6M 28.5M 2024-12
Vertex Pharmaceuticals USD 1.61B 141.2M 2024-12



Neurocrine Biosciences Créances Commerciales - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.